Blood test to monitor minimal residual disease in multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new blood test that looks for tiny amounts of cancer cells left after treatment, using samples from your diagnosis and a simple blood draw. It may help monitor if your remission is lasting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have multiple myeloma and be in strict complete remission (no detectable signs of the disease) for more than 6 months.
- Your hospital must have stored bone marrow and blood samples taken at the time of your initial diagnosis.
- You need to understand and read Danish.
- You must not have a bleeding disorder or very low platelet counts (below 20 mia/L).
- You must be willing to give written consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a simple blood test can help track multiple myeloma. It will measure a protein called soluble BCMA that may indicate how active the disease is, potentially helping doctors monitor patients without frequent bone marrow tests.
This study tests a genetic technology (ClonoSeq-based) to detect very small amounts of multiple myeloma that may remain after treatment. It may help doctors better track how well treatment is working and predict how the disease responds over time.
This study looks at whether small leftover signs of multiple myeloma in blood or bone marrow (called measurable residual disease, or MRD) can predict how well treatment works. It involves people already taking study treatment in a larger trial and checks results about two years later to see who benefits most.
This trial studies myeloma (and closely related blood disorders) by using extra blood or bone marrow samples for lab research. It aims to help discover new ways to understand or treat myeloma.
This study looks at simple blood test results from people newly diagnosed with multiple myeloma to see if those results can help predict how the disease may progress. It aims to find patterns in the blood that might guide future treatment decisions without any extra procedures or drugs.
This study looks at stored blood (serum) samples to see whether a lab test called MALDI-TOF mass spectrometry can help analyze multiple myeloma proteins. If you have multiple myeloma (or are a healthy matched control), your existing lab samples may be used for testing.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.